Larimar Therapeutics Inc (STU:ZA71) Transcripts

Larimar Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 14, 2026
Larimar Therapeutics Inc To Provide a Program Update Transcript
Feb 12, 2024
Larimar Therapeutics Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript
Nov 07, 2023
Larimar Therapeutics Inc To Discuss Phase 2 dose exploration trial of CTI-1601 Transcript
Jul 25, 2023
Larimar Therapeutics Inc CTI-1601 May 2023 Program Update Conference Call Transcript
May 15, 2023
Larimar Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Apr 04, 2023
9Larimar Therapeutics Inc at Guggenheim Healthcare Talks: Immunology and Neurology Day Transcript
Nov 15, 2022
Larimar Therapeutics Inc To Discuss Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 Transcript
Sep 14, 2022
Larimar Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Jul 15, 2021
Q1 2021 Larimar Therapeutics Inc Earnings Call Transcript
May 11, 2021

€10.5 (-3.67%)

Earnings
Zafgen Inc and Chondrial Therapeutics Announce Definitive Merger Agreement - M&A Call Transcript
Dec 18, 2019
Q4 2018 Zafgen Inc Earnings Call Transcript
Mar 11, 2019

Earnings

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.